H.B. NO. <sup>1659</sup> H.D. 3 S.D. 1

# A BILL FOR AN ACT

RELATING TO HEALTH.

### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECT	ION 1. Chapter 328, Hawaii Revised Statutes, is	
2	amended by adding a new section to part I to be appropriately		
3	designated and to read as follows:		
4	"§328- Customized patient medication package. (a) A		
5	pharmacy	may provide a customized patient medication package to	
6	any person; provided that:		
7	(1)	The pharmacy has obtained the consent of the patient,	
8		patient's caregiver, patient's guardian, or	
9		prescribing practitioner; provided that the consent	
10		may be communicated in writing, orally, or by	
11		electronic transmission; provided further that the	
12		format of the consent shall be identified on the	
13		prescription record required to be maintained under	
14		section 328-17.7;	
15	(2)	The consent is accompanied by the patient's current	
16		prescription; and	

2020-1994 HB1659 SD1 SMA.doc

## H.B. NO. <sup>1659</sup> H.D. 3 S.D. 1

,

1	(3) The customized patient medication package meets the	
2	requirements of section 328-16.	
3	(b) As used in this section, "customized patient	
4	medication package" means a package that is prepared by a	
5	pharmacist for a specific patient and contains one or more	
6	prescribed solid oral dosage forms."	
7	SECTION 2. Section 329-14, Hawaii Revised Statutes, is	
8	amended to read as follows:	
9	"(b) Any of the following opiates, including their	
10	isomers, esters, ethers, salts, and salts of isomers, esters,	
11	and ethers, unless specifically excepted, whenever the existence	
12	of these isomers, esters, ethers, and salts is possible within	
13	the specific chemical designation:	
14	(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-	
15	<pre>phenethyl)-4-piperidinyl]-N-phenylacetamide);</pre>	
16	(2) Acetylmethadol;	
17	(3) Allylprodine;	
18	(4) Alphacetylmethadol (except levo-alphacetylmethadol,	
19	levomethadyl acetate, or LAAM);	
20	(5) Alphameprodine;	
21	(6) Alphamethadol;	

2020-1994 HB1659 SD1 SMA.doc

## H.B. NO. <sup>1659</sup> H.D. 3 S.D. 1

1	(7)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
2		phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
3		2-phenylethyl)-4-(N-propanilido) piperidine);
4	(8)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
5		<pre>thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);</pre>
6	(9)	Benzethidine;
7	(10)	Betacetylmethadol;
8	(11)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
9		<pre>piperidinyl]-N-phenylpropanamide);</pre>
10	(12)	Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
11		phenethyl)-3-methyl-4-piperidinyl]-N-
12		phenylpropanamide);
13	(13)	Betameprodine;
14	(14)	Betamethadol;
15	(15)	Betaprodine;
16	(16)	Clonitazene;
17	(17)	Dextromoramide;
18	(18)	Diampromide;
19	(19)	Diethylthiambutene;
20	(20)	Difenoxin;
21	(21)	Dimenoxadol;



## H.B. NO. <sup>1659</sup> H.D. 3 S.D. 1

- 1 (22)Dimepheptanol; 2 (23) Dimethylthiambutene; 3 (24) Dioxaphetyl butyrate; 4 (25)Dipipanone; 5 (26) Ethylmethylthiambutene; 6 (27) Etonitazene; 7 (28)Etoxeridine; 8 (29) Furethidine; 9 (30)Hydroxypethidine; 10 (31) Ketobemidone; 11 (32) Levomoramide; 12 (33) Levophenacylmorphan; 13 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-14 piperidyl]-N-phenylpropanamide); 15 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-16 4-piperidinyl]-N-phenylpropanamide); 17 Morpheridine; (36) 18 (37)MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); 19 (38) Noracymethadol; 20 (39) Norlevorphanol;
- 21 (40) Normethadone;



# H.B. NO. <sup>1659</sup> H.D. 3 S.D. 1

1	(41)	Norpipanone;
2	(42)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
3		phenethyl)-4-piperidinyl] propanamide;
4	(43)	<pre>PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;</pre>
5	(44)	Phenadoxone;
6	(45)	Phenampromide;
7	(46)	Phenomorphan;
8	(47)	Phenoperidine;
9	. (48)	Piritramide;
10	(49)	Proheptazine;
11	(50)	Properidine;
12	(51)	Propiram;
13	(52)	Racemoramide;
14	(53)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
15		<pre>piperidinyl]-propanamide);</pre>
16	(54)	Tilidine;
17	(55)	Trimeperidine;
18	(56)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
19		(benzylfentanyl), its optical isomers, salts, and
20		salts of isomers;

.

# H.B. NO. <sup>1659</sup> H.D. 3 S.D. 1

1	(57)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-
2		phenylpropanamide (thenylfentanyl), its optical
3		isomers, salts, and salts of isomers;
4	(58)	N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
5		(acetyl fentanyl), its optical, positional, and
6		geometric isomers, salts, and salts of isomers;
7	(59)	AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
8		cyclohexylmethyl]benzamide), its isomers, esters,
9		ethers, salts, and salts of isomers, esters, and
10		ethers;
11	(60)	N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
12		isomers, esters, ethers, salts, and salts of isomers,
13		esters, and ethers (Other names: Butyryl fentanyl);
14	(61)	N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-
15		yl]-N-phenylpropionamide, its isomers, esters, ethers,
16		salts, and salts of isomers, esters, and ethers (Other
17		names: beta-hydroxythiofentanyl);
18	(62)	N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-
19		carboxamide, its isomers, esters, ethers, salts, and
20		salts of isomers, esters, and ethers (Other names:
21		Furanyl fentanyl); [ <del>and</del> ]

2020-1994 HB1659 SD1 SMA.doc

6

## H.B. NO. <sup>1659</sup> H.D. 3 S.D. 1

1	(63)	3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
2		methylbenzamide, its isomers, esters, ethers, salts,
3		and salts of isomers, esters, and ethers (Other names:
4		U-47700) [ <del>.</del> ] <u>;</u>
5	(64)	4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl
6		fenranyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-
7		4-yl)isobutyramide];
8	(65)	Acryl fentanyl or acryloylfentanyl [N-(1-
9		phenethylpiperidin-4-yl)-N-phenylacrylamide]; and
10	(66)	Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-
11		phenethylpiprtidin-4-yl)acetamide]."
12	SECT	ION 3. Statutory material to be repealed is bracketed
13	and stric	ken. New statutory material is underscored.
14	SECT	ION 4. This Act shall take effect upon its approval.





#### Report Title:

Prescription Drugs; Pharmacy; Customized Patient Medication Packages; Schedule I Controlled Substances

### Description:

Authorizes a pharmacy to provide a customized patient medication package to any person upon consent, with a valid prescription, and in compliance with labeling and dispensing requirements. Adds certain substances to the list of Hawaii's Schedule I controlled substances. (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

